Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Oxurion Stock Quote

Oxurion (OTC: TBGNF)

Oxurion Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
TBGNF -93.49% -95.85% -47.09% -99%
S&P +20.88% +72.88% +11.56% +231%

Oxurion Company Info

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. It operates under JETREA brand name. The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium.

News & Analysis

Featured Article

ThromboGenics Plays Long Game for Eye Disease

ThromboGenics's expansion from the small neighborhood of vitreomacular adhesion to the big city of diabetic macular edema is a solid long term strategy for building is pipeline of ophthalmologic drugs.

Catherine Shaffer  |  Mar 26, 2014

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services